Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer

Journal of Clinical Investigation

Volumn 107, Issue 2, 2001, Pages 135-142

  Yamamoto, Yumi ^a   Gaynor, Richard B ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; CYTOKINE; FLAVONOID; GLUCOCORTICOID; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROTEASOME;

APOPTOSIS; CANCER; CELL PROLIFERATION; GENE ACTIVATION; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0035139792     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11914     Document Type: Review

References (47)

1. The NF-κB and IκB proteins: New discoveries and insights
2. Activators and target genes of Rel/NF-κB transcription factors
3. The regulation and roles of Rel/NF-κB transcription factors during lymphocyte activation
4. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses
5. Control of apoptosis by Rel/NFkappaB transcription factors
6. NF-κB anti-apoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
7. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival
8. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis
9. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
10. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1
11. NF-κB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition
12. NF-κB: A key role in inflammatory diseases
13. NF-κB: Pivotal mediator or innocent bystander in atherogenesis?
14. NF-κB in neuronal plasticity and neurodegenerative disorders
15. Immunological aspects of allergic asthma
16. Role of cytokines in rheumatoid arthritis
17. Inflammatory bowel disease
18. The pathogenesis of atherosclerosis: A perspective for the 1990s
19. Inhibition of NF-κB potentiates amyloid beta-mediated neuronal apoptosis
20. Aberrant rel/NF-κB genes and activity in human cancer
21. Bridging the gap: Composition, regulation, and physiological function of the IκB kinase complex
22. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
23. Suppression of TNF-α-induced apoptosis by NF-κB
24. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
25. Control of apoptosis, oncogenesis, and cancer therapy resistance by the transcription factor NF-κB
26. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis
27. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids
28. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation
29. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors
30. Nuclear integration of glucocorticoid receptor and NF-κB signaling by CREB-binding protein and steroid receptor coactivator-1
31. Glucocorticoids repress NF-kappa B-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell
32. Towards a better aspirin
33. Salicylates inhibit IκBα phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration
34. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
35. Sulindac inhibits activation of the NF-κB pathway
36. Sulfasalazine: A potent and specific inhibitor of NF-κB
37. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
38. Calcineurin acts in synergy with PMA to inactivate IκB/MAD3, an inhibitor of NF-κB
39. Cyclosporine A is a non-competitive inhibitor of proteasome activity and prevents NF-κB activation
40. Cyclosporin A interferes with the inducible degradation of NF-κB inhibitors, but not with the processing of p105/NF-κB1 in T cells
41. FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells
42. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
43. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
44. Proteasome inhibitors: A novel class of potent and effective antitumor agents
45. Suppression of nitric oxide synthase and the down-regulation of the activation of NF-κB in macrophages by resveratrol
46. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase
47. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation